Prothena Corp. Public Ltd. Co.
Present preclinical data at ADPD 2021
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 31 Mar 2021
- Delivered
- 11 Mar 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Preclinical data to be presented in March at ADPD 2021”
What we found
Evidence strength A What the grades mean
Prothena presented new preclinical data regarding PRX005 at the AD/PD 2021 conference on March 11, 2021.
-
A Prothena Corp. Public Ltd. Co. 10-Q filed 2021-05-11
“On March 11, 2021, we gave an oral presentation at AD/PD 2021 highlighting new preclinical data demonstrating that targeting the microtubule binding region (MTBR) of tau with PRX005 resulted in superior attributes” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
- Deliverable
- Preclinical data
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Prothena Corp. Public Ltd. Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-PRTA-023660 · Corrections policy